{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:10:03Z","timestamp":1793419803770,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.annonc.2026.04.013","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:06:11Z","timestamp":1780873571000},"page":"1178-1185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6817-0693","authenticated-orcid":false,"given":"A.H.-C.","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.T.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8958-5222","authenticated-orcid":false,"given":"Y.-C.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1168-2723","authenticated-orcid":false,"given":"M.C.","family":"Sant\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Meschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1074-0229","authenticated-orcid":false,"given":"P.","family":"Mateo-Kubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10469","key":"10.1016\/j.annonc.2026.04.013_bib1","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/S0140-6736(24)01548-4","article-title":"National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.013_bib2","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer--viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.013_bib3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.annonc.2026.04.013_bib4","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJMcibr2409089","article-title":"Discovery of GLP-1-based drugs for the treatment of obesity","volume":"392","author":"Drucker","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2026.04.013_bib5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.7326\/M24-0019","article-title":"Shifting trends in the indication of glucagon-like peptide-1 receptor agonist prescriptions: a nationwide analysis","volume":"177","author":"Yeo","year":"2024","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.013_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2026.04.013_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.013_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.annonc.2026.04.013_bib9","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.013_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2026.04.013_bib11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2026.04.013_bib12","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1210\/en.2011-1201","article-title":"Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells","volume":"152","author":"Koehler","year":"2011","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.annonc.2026.04.013_bib13","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 receptor agonists and cancer risk in adults with obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2026.04.013_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"24","key":"10.1016\/j.annonc.2026.04.013_bib15","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.013_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.013_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2102605","article-title":"Multisystem inflammatory syndrome in children - initial therapy and outcomes","volume":"385","author":"Son","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2026.04.013_bib18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jama.2019.21558","article-title":"Using propensity score methods to create target populations in observational clinical research","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2026.04.013_bib19","series-title":"TriNetX dataset","year":"2025"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.013_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5683","article-title":"Core concepts in pharmacoepidemiology: measurement of medication exposure in routinely collected healthcare data for causal inference studies in pharmacoepidemiology","volume":"33","author":"Thai","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.annonc.2026.04.013_bib22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.013_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57232","article-title":"Longitudinal analysis of obesity drug use and public awareness","volume":"8","author":"Berning","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.annonc.2026.04.013_bib24","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.annonc.2026.04.013_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"446","key":"10.1016\/j.annonc.2026.04.013_bib26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.013_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/aje\/kwq341","article-title":"Reverse causation and illness-related weight loss in observational studies of body weight and mortality","volume":"173","author":"Flegal","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.013_bib28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/pds.3386","article-title":"Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy","volume":"22","author":"Mack","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.013_bib29","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.annonc.2026.04.013_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107866","article-title":"Sex differences in the weight response to GLP-1RA in people with type 2 diabetes: a long-term longitudinal real-world study","volume":"219","author":"Marassi","year":"2025","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.annonc.2026.04.013_bib31","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2147\/PPA.S277676","article-title":"Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States","volume":"14","author":"Weiss","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.013_bib32","first-page":"111","article-title":"Cancer statistics for African American and Black people, 2025","volume":"75","author":"Saka","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.013_bib33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1186\/s12885-018-4570-8","article-title":"Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer","volume":"18","author":"Kanda","year":"2018","journal-title":"BMC Cancer"},{"issue":"35","key":"10.1016\/j.annonc.2026.04.013_bib34","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1200\/JCO.2016.69.4638","article-title":"Addressing the role of obesity in endometrial cancer risk, prevention, and treatment","volume":"34","author":"Onstad","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2026.04.013_bib35","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"issue":"12 suppl 2","key":"10.1016\/j.annonc.2026.04.013_bib36","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro Oncol"},{"issue":"20","key":"10.1016\/j.annonc.2026.04.013_bib37","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMp2400978","article-title":"Fair allocation of GLP-1 and dual GLP-1-GIP receptor agonists","volume":"390","author":"Emanuel","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.013_bib38","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:59:59Z","timestamp":1785283199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426001572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0923753426001572"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.013","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}